Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1067/mcp.2001.114926 http://scihub22266oqcxt.onion/10.1067/mcp.2001.114926 11372005!ä!11372005 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Pharmacol+Ther 2001 ; 69 (5): 365-71 Nephropedia Template TP {{tp|p=11372005|t=2001. Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study |pdf=|usr=}}{{11372005}} gab.com Text Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study JO: Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=11372005 #FOAvip BACKGROUND: Magnesium has been shown to be helpful in the treatment of acute exacerbations of asthma. Conflicting data exist concerning the effect of magnesium on bronchial hyperreactivity. METHODS: We performed a randomized, double-blind, placebo-controlled study to investigate the effect of intravenous magnesium sulfate on bronchial reactivity to metacholine in 30 subjects with bronchial hyperreactivity. Two days after baseline metacholine provocation, 20 subjects received 0.3 mmol/kg/h of intravenous magnesium sulfate and 10 subjects received normal saline solution. Metacholine provocation was repeated 30 minutes after the initiation of the magnesium or placebo infusion. RESULTS: The difference of the postinterventional minus the baseline provocative dose of metacholine required to decrease the forced expiratory volume in 1 second by 20% (PC20) was significantly higher in the magnesium group compared with the placebo group (0.48 +/- 0.46 mg/mL versus 0.05 +/- 0.73 mg/mL, P = .028). In the magnesium group, the PC(20) significantly increased (from 0.83 +/- 0.54 mg/mL to 1.31 +/- 0.66 mg/mL, P = .0001), whereas there was no change in the placebo group (0.86 +/- 0.52 mg/mL to 0.91 +/- 0.54 mg/mL, P = .83). CONCLUSIONS: In the magnesium group, 30% of the subjects reached a normal PC(20) compared with 10% in the placebo group. We conclude that intravenous magnesium sulfate significantly improved bronchial hyperreactivity and may serve as an adjunct to standard treatment. Twit Text FOAVip Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study ????Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=11372005 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=11372005 #FOAvip English Wikipedia <ref>{{Cite pmid|11372005}}</ref> Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study #MMPMID11372005 Schenk P; Vonbank K; Schnack B; Haber P; Lehr S; Smetana R Clin Pharmacol Ther 2001[May]; 69 (5): 365-71 PMID11372005show ga BACKGROUND: Magnesium has been shown to be helpful in the treatment of acute exacerbations of asthma. Conflicting data exist concerning the effect of magnesium on bronchial hyperreactivity. METHODS: We performed a randomized, double-blind, placebo-controlled study to investigate the effect of intravenous magnesium sulfate on bronchial reactivity to metacholine in 30 subjects with bronchial hyperreactivity. Two days after baseline metacholine provocation, 20 subjects received 0.3 mmol/kg/h of intravenous magnesium sulfate and 10 subjects received normal saline solution. Metacholine provocation was repeated 30 minutes after the initiation of the magnesium or placebo infusion. RESULTS: The difference of the postinterventional minus the baseline provocative dose of metacholine required to decrease the forced expiratory volume in 1 second by 20% (PC20) was significantly higher in the magnesium group compared with the placebo group (0.48 +/- 0.46 mg/mL versus 0.05 +/- 0.73 mg/mL, P = .028). In the magnesium group, the PC(20) significantly increased (from 0.83 +/- 0.54 mg/mL to 1.31 +/- 0.66 mg/mL, P = .0001), whereas there was no change in the placebo group (0.86 +/- 0.52 mg/mL to 0.91 +/- 0.54 mg/mL, P = .83). CONCLUSIONS: In the magnesium group, 30% of the subjects reached a normal PC(20) compared with 10% in the placebo group. We conclude that intravenous magnesium sulfate significantly improved bronchial hyperreactivity and may serve as an adjunct to standard treatment. |Adult[MESH] |Analgesics/administration & dosage/blood/*therapeutic use[MESH] |Bronchial Hyperreactivity/*drug therapy[MESH] |Bronchial Provocation Tests[MESH] |Double-Blind Method[MESH] |Female[MESH] |Humans[MESH] |Infusions, Intravenous[MESH] |Magnesium Sulfate/administration & dosage/blood/*therapeutic use[MESH] |Male[MESH]Intravenous magnesium sulfate for bronchial hyperreactivity: a randomi(epmc).pdf DeepDyve Pubget Overpricing